연구동향 분석
박사

Xanthine oxidase 억제제 경구 투여 후 요산(Uric acid) 생성 변화 예측을 위한 집단 약동학/약력학 모델 개발

윤성혜 2016년

논문상세정보
인용/피인용
' Xanthine oxidase 억제제 경구 투여 후 요산(Uric acid) 생성 변화 예측을 위한 집단 약동학/약력학 모델 개발' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 의료과학 약
  • 약동학
  • 약력학
  • 요산(uric acid)
  • 잰틴 산화효소 억제제(xanthine oxidase inhibitor)
  • 집단 약동학-약력학 분석
  • 통풍
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
3,980 0

0.0%

' Xanthine oxidase 억제제 경구 투여 후 요산(Uric acid) 생성 변화 예측을 위한 집단 약동학/약력학 모델 개발' 의 참고문헌

  • Yue TF, Gutman AB. Effect of Allopurinol (4-Hydroxypyrazolo- (3,4-D)Pyrimidine) on Serum and Urinary Uric Acid in Primary and Secondary Gout. The American journal of medicine. 1964;37:885-98.
  • Wyngaarden JB. Allopurinol and xanthine nephropathy. The New England journal of medicine. 1970;283(7):371-2.
  • Wu EQ, Patel PA, Yu AP, Mody RR, Cahill KE, Tang J, et al. Disease-related and all-cause health care costs of elderly patients with gout. Journal of managed care pharmacy : JMCP. 2008;14(2):164-75.
  • Wempe MF, Quade B, Jutabha P, Iwen T, Frick M, Rice PJ, et al. Human uric acid transporter 1 (hURAT1): an inhibitor structure-activity relationship (SAR) study. Nucleosides, nucleotides & nucleic acids. 2011;30(12):1312-23.
  • Waring WS. Uric acid: an important antioxidant in acute ischaemic stroke. QJM : monthly journal of the Association of Physicians. 2002;95(10):691-3.
  • Waring WS, Webb DJ, Maxwell SR. Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. Journal of cardiovascular pharmacology. 2001;38(3):365-71.
  • Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. The Journal of rheumatology. 2004;31(8):1582-7.
  • Turnheim K, Krivanek P, Oberbauer R. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. British journal of clinical pharmacology. 1999;48(4):501-9.
  • Tsai TF, Yeh TY. Allopurinol in dermatology. American journal of clinical dermatology. 2010;11(4):225-32.
  • Torres RJ, de Miguel E, Bailen R, Banegas JR, Puig JG. Tubular urate transporter gene polymorphisms differentiate patients with gout who have normal and decreased urinary uric Acid excretion. The Journal of rheumatology. 2014;41(9):1863-70.
  • Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, et al. Confidence interval criteria for assessment of dose proportionality. Pharmaceutical research. 2000;17(10):1278-83.
  • Singh JA, Hodges JS, Asch SM. Opportunities for improving medication use and monitoring in gout. Annals of the rheumatic diseases. 2009;68(8):1265-70.
  • Sato M, Mamada H, Anzai N, Shirasaka Y, Nakanishi T, Tamai I. Renal secretion of uric acid by organic anion transporter 2 (OAT2/SLC22A7) in human. Biological & pharmaceutical bulletin. 2010;33(3):498-503.
  • Pasalic D, Marinkovic N, Feher-Turkovic L. Uric acid as one of the important factors in multifactorial disorders--facts and controversies. Biochemia medica. 2012;22(1):63-75.
  • Marro PJ, Baumgart S, Delivoria-Papadopoulos M, Zirin S, Corcoran L, McGaurn SP, et al. Purine metabolism and inhibition of xanthine oxidase in severely hypoxic neonates going onto extracorporeal membrane oxygenation. Pediatric research. 1997;41(4 Pt 1):513-20.
  • Marangella M. Uric acid elimination in the urine. Pathophysiological implications. Contributions to nephrology. 2005;147:132-48.
  • Lee CH, Sung NY. The Prevalence and Features of Korean Gout Patients Using the National Health Insurance Corporation Database. Journal of Rheumatic Diseases. 2011;18(2):94-100.
  • LaRosa C, McMullen L, Bakdash S, Ellis D, Krishnamurti L, Wu HY, et al. Acute renal failure from xanthine nephropathy during management of acute leukemia. Pediatr Nephrol. 2007;22(1):132-5.
  • Kraupp M, Marz R. Membrane transport of nucleobases: interaction with inhibitors. General pharmacology. 1995;26(6):1185-90.
  • Kim KY, Ralph Schumacher H, Hunsche E, Wertheimer AI, Kong SX. A literature review of the epidemiology and treatment of acute gout. Clinical therapeutics. 2003;25(6):1593-617.
  • Khosravan R, Grabowski BA, Wu JT, Joseph-Ridge N, Vernillet L. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. Clinical pharmacokinetics. 2006;45(8):821-41.
  • Katsiki N, Karagiannis A, Athyros VG, Mikhailidis DP. Hyperuricaemia: more than just a cause of gout? Journal of cardiovascular medicine. 2013;14(6):397-402.
  • Kang DH, Nakagawa T. Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease. Seminars in nephrology. 2005;25(1):43-9.
  • Kanemitsu H, Tamura A, Kirino T, Oka H, Sano K, Iwamoto T, et al. Allopurinol inhibits uric acid accumulation in the rat brain following focal cerebral ischemia. Brain research. 1989;499(2):367-70.
  • Kanbay M, Segal M, Afsar B, Kang DH, Rodriguez-Iturbe B, Johnson RJ. The role of uric acid in the pathogenesis of human cardiovascular disease. Heart. 2013;99(11):759-66.
  • Hummel J, McKendrick S, Brindley C, French R. Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharmaceutical statistics. 2009;8(1):38-49.
  • Hosomi A, Nakanishi T, Fujita T, Tamai I. Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2. PloS one. 2012;7(2):e30456.
  • Hiroshige K, Takasugi M, Yuu K, Kuroiwa A. Pharmacologic evaluation of the renal handling of uric acid and oxypurines. Nihon Jinzo Gakkai shi. 1994;36(11):1268-75.
  • Hak AE, Choi HK. Lifestyle and gout. Current opinion in rheumatology. 2008;20(2):179-86.
  • David SN. Gout, basic science and clinical practice: Springer; 2013.
  • Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116(8):894-900.
  • Becker BF. Towards the physiological function of uric acid. Free radical biology & medicine. 1993;14(6):615-31.
  • Becker BF, Reinholz N, Leipert B, Raschke P, Permanetter B, Gerlach E. Role of uric acid as an endogenous radical scavenger and antioxidant. Chest. 1991;100(3 Suppl):176S-81S.
  • Band PR, Silverberg DS, Henderson JF, Ulan RA, Wensel RH, Banerjee TK, et al. Xanthine nephropathy in a patient with lymphosarcoma treated with allopurinol. The New England journal of medicine. 1970;283(7):354-7.
  • Baker JF, Schumacher HR. Update on gout and hyperuricemia. International journal of clinical practice. 2010;64(3):371-7.